HCM

HCM

HUTCHMED (China) Limited American Depositary Shares

$17.720+0.000 (0.000%)

Precio en Tiempo Real

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$17.720

Máximo

$17.720

Mínimo

$17.720

Volumen

0.07M

Fundamentos de la Empresa

Estadísticas de Negociación

Noticias Relacionadas

PR Newswire

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high...

Ver más
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma
GlobeNewswire

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today jointly

Ver más
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
GlobeNewswire

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds

Ver más
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.